147 related articles for article (PubMed ID: 16725012)
1. Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer.
Petri AL; Høgdall E; Christensen IJ; Kjaer SK; Blaakaer J; Høgdall CK
APMIS; 2006 May; 114(5):359-63. PubMed ID: 16725012
[TBL] [Abstract][Full Text] [Related]
2. Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre.
Osman N; O'Leary N; Mulcahy E; Barrett N; Wallis F; Hickey K; Gupta R
Ir Med J; 2008 Sep; 101(8):245-7. PubMed ID: 18990955
[TBL] [Abstract][Full Text] [Related]
3. Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study.
Paramasivam S; Tripcony L; Crandon A; Quinn M; Hammond I; Marsden D; Proietto A; Davy M; Carter J; Nicklin J; Perrin L; Obermair A
J Clin Oncol; 2005 Sep; 23(25):5938-42. PubMed ID: 16087942
[TBL] [Abstract][Full Text] [Related]
4. [Correlation of preoperative serum vascular endothelial growth factor level with CA125 level in patients with epithelial ovarian cancer and its prognostic value].
Tan XJ; Lang JH; Shen K; Wang L; Wu M; Xu XY
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):9-12. PubMed ID: 18366924
[TBL] [Abstract][Full Text] [Related]
5. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of CA 125 in ovarian cyst fluid of patients with epithelial ovarian cancer.
Kolwijck E; Span PN; Thomas CM; Bulten J; Sweep FC; Massuger LF
Oncol Rep; 2010 Feb; 23(2):579-84. PubMed ID: 20043124
[TBL] [Abstract][Full Text] [Related]
7. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
[TBL] [Abstract][Full Text] [Related]
8. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
9. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer.
Hefler LA; Concin N; Hofstetter G; Marth C; Mustea A; Sehouli J; Zeillinger R; Leipold H; Lass H; Grimm C; Tempfer CB; Reinthaller A
Clin Cancer Res; 2008 Feb; 14(3):710-4. PubMed ID: 18245530
[TBL] [Abstract][Full Text] [Related]
10. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.
Baron AT; Cora EM; Lafky JM; Boardman CH; Buenafe MC; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):103-13. PubMed ID: 12582019
[TBL] [Abstract][Full Text] [Related]
11. Serum tetranectin is a significant prognostic marker in ovarian cancer patients.
Begum FD; Høgdall E; Christensen IJ; Kjaer SK; Blaakaer J; Christensen L; Høgdall C
Acta Obstet Gynecol Scand; 2010; 89(2):190-8. PubMed ID: 20121334
[TBL] [Abstract][Full Text] [Related]
12. A new prognostic model for FIGO stage 1 epithelial ovarian cancer.
Obermair A; Fuller A; Lopez-Varela E; van Gorp T; Vergote I; Eaton L; Fowler J; Quinn M; Hammond I; Marsden D; Proietto A; Carter J; Davy M; Tripcony L; Abu-Rustum N
Gynecol Oncol; 2007 Mar; 104(3):607-11. PubMed ID: 17092548
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer.
Høgdall CK; Nørgaard-Pedersen B; Mogensen O
Anticancer Res; 2002; 22(3):1765-8. PubMed ID: 12168866
[TBL] [Abstract][Full Text] [Related]
14. Serial determinations of aminoterminal propeptide of type III procollagen (PIIINP) and prognosis in ovarian cancer; comparison to CA125.
Simojoki M; Santala M; Risteli J; Risteli L; Kauppila A
Anticancer Res; 2000; 20(6C):4655-60. PubMed ID: 11205196
[TBL] [Abstract][Full Text] [Related]
15. The role of serum CA-125 levels in early-stage epithelial ovarian cancer on preoperative CT and MRI.
Kim HS; Kim JW; Cho JY; Chung HH; Park NH; Song YS; Kim SH; Kang SB
Eur J Surg Oncol; 2009 Aug; 35(8):870-6. PubMed ID: 19179039
[TBL] [Abstract][Full Text] [Related]
16. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
17. [Treatment and prognostic factors for stage IV epithelial ovarian cancer].
Wu M; Shen K; Lang J
Zhonghua Fu Chan Ke Za Zhi; 2000 Apr; 35(4):200-3. PubMed ID: 11776158
[TBL] [Abstract][Full Text] [Related]
18. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis.
Luo LY; Katsaros D; Scorilas A; Fracchioli S; Bellino R; van Gramberen M; de Bruijn H; Henrik A; Stenman UH; Massobrio M; van der Zee AG; Vergote I; Diamandis EP
Cancer Res; 2003 Feb; 63(4):807-11. PubMed ID: 12591730
[TBL] [Abstract][Full Text] [Related]
19. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
Kang WD; Choi HS; Kim SM
Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
[TBL] [Abstract][Full Text] [Related]
20. A study to evaluate the utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer.
Gilani MM; Karimi Zarchi M; Ghaemmaghami F; Behtash N; Mousavi AS; Ansaripoor S
Gynecol Oncol; 2007 Jun; 105(3):780-3. PubMed ID: 17433423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
